Enzymotec announces K-REAL clinicals, trademark

Enzymotec announces K-REAL clinicals, trademark

Company announced the acceptance for future publication of its clinical study results evaluating the health benefits of K-REAL krill oil compared with fish oil.

Enzymotec Ltd. (Nasdaq:ENZY), a developer, manufacturer and marketer of innovative bio-active lipid ingredients, announced the acceptance for future publication of its clinical study results evaluating the health benefits of K-REAL, krill oil, compared with fish oil.

The article manuscript titled "Enhanced increase of omega-3 index in healthy individuals with response to 4-week n-3 fatty acid supplementation from krill oil versus fish oil" was accepted for publication in the peer-reviewed Journal of Lipids in Health and Disease. The study was conducted by the Richardson Centre for Functional Foods and Nutraceuticals, Winnipeg, Canada.

Enzymotec's double blind, randomized, placebo-controlled crossover study included three treatments periods. Each treatment period lasted four weeks and was separated by washout phases of eight weeks. The study aimed to evaluate the effect of 500 mg K-REAL with three capsules taken in the morning and three at night. Differences between krill oil, fish oil, and placebo control interventions were analyzed.

Study results indicate that K-REAL, krill oil, is more effective than fish oil in reducing n-6:n-3 polyunsaturated fatty acid ratios, and improving the level of EPA and DHA accumulated in the red blood cells (omega-3 index). Due to structural differences, bioavailability of krill oil, a phospholipid based oil, could be higher than fish oil, a triglyceride-based oil, conferring properties that render it more effective than fish oil in increasing omega-3 index and thereby, reducing cardiovascular disease risk.*

"We are pleased with the results of the study which are consistent with previous clinical studies on other ingredients developed and manufactured by Enzymotec," said Dr. Ariel Katz, president and chief executive officer of Enzymotec Ltd. "We will continue to capitalize on consumer trends towards supplementing their diets with premium health and wellness products like our K-REAL, krill oil."

"We are very pleased with the results of this study. The assumption that omega-3 fatty acids are better absorbed when they are bound to phospholipids rather than triglycerides, was suggested as one of the main benefits of krill oil. However, nobody was able to show it so far. This is the first well designed study proving that consumption of krill oil is more efficient than fish oil in elevating the level of omega-3 fatty acids in the red blood cells," said Dr. Peter Jones, the principal investigator of this study.

K-REAL is a family of solutions extracted from sustained Antarctic Krill. It is comprised from a mixture of natural phospholipids conjugated to EPA and DHA, astaxanthin and TG with EPA and DHA. K-REAL by Enzymotec has been proven to be significantly more effective than fish oil in increasing omega-3 index.

*Supportive but not conclusive research shows that consumption of EPA and DHA omega-3 fatty acids may reduce the risk of coronary heart disease.

 

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish